iqvia report ep beat in-lin revenu adjust ebitda ta growth
took step back csm segment better expect
revenu guidanc come midpoint due fx full-year
adjust ebitda adjust ep guidanc rang narrow re-affirmed
midpoint
number iqvia report revenu vs pjc/consensu estim
ta growth moder third consecut quarter
segment revenu less model upsid driven
 solut grew csm defi our/consensu
expect post upsid pjc estim follow six quarter
y/i declin adjust ebitda high end guidanc rang
ahead pjc/consensu adjust ep beat pjc/consensu
high end guidanc fourth quarter expect ta
growth continu modest deceler tougher comp growth
acceler ytd csm enjoy continu posit momentum end
year flat revenu growth guidanc came due fx actual
fx repres growth y/i midpoint
oce continu gain momentum iqvia platform oce pick new win
quarter bring total client fifteen win competit head-
to-head bid arrang segment leader like veeva rate
notabl win quarter includ top pharma client top pharma client
deploy tool asia deal opportun futur expans
geograph therapeut standpoint
client demand innov continu real world evid rwe side
busi number project enter use extern compar arm cull
person data set curat iqvia quadrupl quarter
sign prefer provid partnership electron clinic outcom assess
ecoa collect data directli patient
chang pharma industri impact spend drug research revers
current increas outsourc trend pharma industri averag leverag
balanc sheet impact opportun
iqvia largest cro industri expertis across major therapeut
oper countri
ep
debt total capit
piper jaffray seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis report read conjunct import disclosur inform
includ attest regul analyst certif found page report follow site
page
page
varianc estimate actual differencey/i changeseq changerevenu technolog analyt solut sale medic solut incom net compani document piper jaffray co actualguidancepjcconsensusrevenu compani document piper jaffray co bloomberg consensu ebitda compani document piper jaffray co bloomberg consensu guid pjcconsensusrevenu ebitda compani document piper jaffray co bloomberg consensu estimatesevolut revenu guidea oct juli feb revenu actual impli midpoint actual consensu compani document piper jaffray co bloomberg consensu estim iqvia
revenu
depreci amort
incom oper
loss extinguish debt
incom tax
incom equiti earn unconsolid affili
equiti earn unconsolid affili
loss incom non control interest
gaap net incom attribut
incom non-control interest
minor interest effect non-gaap adjust
total revenu
incom oper
equiti earn unconsolid affili
loss incom non control interest
current disclosur inform compani locat http /www piperjaffray com/disclosur
